170277-31-3 Usage
Description
Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α), a cytokine involved in inflammatory and immune responses. It is engineered by combining the variable regions of a mouse anti-TNF-α antibody with the constant region of a human IgG1 antibody, resulting in a protein that can specifically bind to and neutralize TNF-α. This interaction helps to reduce inflammation and alleviate symptoms associated with various inflammatory conditions.
Uses
Used in Pharmaceutical Industry:
Infliximab is used as a therapeutic agent for the treatment of various inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and psoriasis. It functions by inhibiting the pro-inflammatory effects of TNF-α, thereby reducing inflammation and improving the quality of life for patients suffering from these conditions.
Used in Cancer Treatment:
Infliximab is also used in combination with other agents, such as harmine and related compounds, to target the transcription factor NF-κB for the treatment of cancers. By inhibiting NF-κB, Infliximab can help suppress the growth and progression of cancer cells, making it a valuable component in cancer therapy regimens.
Check Digit Verification of cas no
The CAS Registry Mumber 170277-31-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,2,7 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 170277-31:
(8*1)+(7*7)+(6*0)+(5*2)+(4*7)+(3*7)+(2*3)+(1*1)=123
123 % 10 = 3
So 170277-31-3 is a valid CAS Registry Number.